Latest News and Press Releases

Preclinical data highlights the therapeutic potential of Ashvattha’s novel CSF1R tyrosine kinase inhibitor (CSF1R dendranib) for multiple sclerosis (MS) based on symptom reduction in the EAE...

Presentations highlight the therapeutic potential of Ashvattha’s novel CSF1R tyrosine kinase inhibitor (CSF1R dendranib) for multiple sclerosis (MS) based on symptom reduction in the EAE preclinical...

The study will evaluate the safety, tolerability, and ability of 18F-OP-801 to cross the blood-brain barrier and selectively target neuroinflammation in individuals with amyotrophic lateral sclerosis,...

REDWOOD CITY, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue...

REDWOOD CITY, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue...

REDWOOD CITY, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue...

Open-label study will evaluate the safety and efficacy of chronic D-4517.2 dosing in patients with wet age-related macular degeneration (wet AMD) or diabetic macular edema (DME)Favorable safety and...

REDWOOD CITY, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue...

Data demonstrated that ASH41020, a novel CSFR1 tyrosine kinase inhibitor ‘dendranib’, directs macrophage polarization toward the anti-inflammatory M2 phenotypeASH41020 treatment lessened disease...

Data will showcase anti-inflammatory and immunomodulatory effects of ASH41020, a novel CSFR1 tyrosine kinase inhibitor ‘dendranib’, in a mouse model of multiple sclerosis  REDWOOD CITY, Calif.,...